DEBRA   Report issue

Foundation Phase 2
Founded: London United Kingdom (1978)

Organization Overview

First Clinical Trial
2018
NCT04153630
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

DEBRA

Active Ingredients

Drugs in Phase 2 Trials (1)

bone marrow derived mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epidermolysis Bullosa (Phase 2)

Epidermolysis Bullosa Dystrophica (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1